BioCryst Pharmaceuticals Stock Forecast, Price & News

+1.15 (+11.29 %)
(As of 04/15/2021 12:00 AM ET)
Today's Range
Now: $11.34
50-Day Range
MA: $11.20
52-Week Range
Now: $11.34
Volume8.46 million shs
Average Volume6.79 million shs
Market Capitalization$2.01 billion
P/E RatioN/A
Dividend YieldN/A
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the development and discovery of novel, oral, and small-molecule medicines. It focuses on the oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The company was founded in 1986 and is headquartered in Durham, NC.
BioCryst Pharmaceuticals logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:BCRX
Phone(919) 859-1302
Year FoundedN/A



Sales & Book Value

Annual Sales$48.83 million
Book Value$0.26 per share


Net Income$-108,900,000.00
Net Margins-233.45%


Market Cap$2.01 billion
Next Earnings Date5/5/2021 (Estimated)


BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 7.6%
April 14, 2021 |
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 4.2%
April 7, 2021 |
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down to $10.35
March 29, 2021 |
BioCryst: Sometimes Good News Isn’t Good Enough
March 24, 2021 |
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 6.8%
March 23, 2021 |
BioCryst Technical Levels To Watch
March 22, 2021 |
BCRX Sep 2021 10.000 put
March 22, 2021 |
See More Headlines


Overall MarketRank

1.33 out of 5 stars

Medical Sector

764th out of 2,021 stocks

Biological Products, Except Diagnostic Industry

104th out of 177 stocks

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+1.15 (+11.29 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BioCryst Pharmaceuticals (NASDAQ:BCRX) Frequently Asked Questions

Is BioCryst Pharmaceuticals a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioCryst Pharmaceuticals stock.
View analyst ratings for BioCryst Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than BioCryst Pharmaceuticals?

Wall Street analysts have given BioCryst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioCryst Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BioCryst Pharmaceuticals' next earnings date?

BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for BioCryst Pharmaceuticals

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its quarterly earnings data on Wednesday, February, 24th. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.09. The biotechnology company had revenue of $4.02 million for the quarter, compared to analyst estimates of $14.72 million. BioCryst Pharmaceuticals had a negative trailing twelve-month return on equity of 328.70% and a negative net margin of 233.45%.
View BioCryst Pharmaceuticals' earnings history

How has BioCryst Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

BioCryst Pharmaceuticals' stock was trading at $2.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BCRX stock has increased by 337.8% and is now trading at $11.34.
View which stocks have been most impacted by COVID-19

What price target have analysts set for BCRX?

11 equities research analysts have issued 12-month price targets for BioCryst Pharmaceuticals' stock. Their forecasts range from $6.00 to $19.00. On average, they expect BioCryst Pharmaceuticals' share price to reach $12.33 in the next twelve months. This suggests a possible upside of 8.8% from the stock's current price.
View analysts' price targets for BioCryst Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are BioCryst Pharmaceuticals' key executives?

BioCryst Pharmaceuticals' management team includes the following people:
  • Jon P. Stonehouse, President, Chief Executive Officer & Director
  • Anthony Doyle, Chief Financial Officer & Senior Vice President
  • William P. Sheridan, Chief Medical Officer & Senior Vice President
  • Helen M. Thackray, Director, Chief Research & Development Officer
  • Alane P. Barnes, Secretary, Chief Legal Officer & Senior VP

What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

2 employees have rated BioCryst Pharmaceuticals CEO Jon P. Stonehouse on Jon P. Stonehouse has an approval rating of 40% among BioCryst Pharmaceuticals' employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BioCryst Pharmaceuticals' key competitors?

What other stocks do shareholders of BioCryst Pharmaceuticals own?

What is BioCryst Pharmaceuticals' stock symbol?

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Edge Wealth Management LLC (0.03%), First Hawaiian Bank (0.03%), Valeo Financial Advisors LLC (0.02%) and Pacer Advisors Inc. (0.00%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Anthony Doyle, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, Steve Aselage and Thomas R Staab II.
View institutional ownership trends for BioCryst Pharmaceuticals

Which institutional investors are selling BioCryst Pharmaceuticals stock?

BCRX stock was sold by a variety of institutional investors in the last quarter, including Edge Wealth Management LLC, First Hawaiian Bank, Pacer Advisors Inc., and Valeo Financial Advisors LLC.
View insider buying and selling activity for BioCryst Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioCryst Pharmaceuticals' stock price today?

One share of BCRX stock can currently be purchased for approximately $11.34.

How much money does BioCryst Pharmaceuticals make?

BioCryst Pharmaceuticals has a market capitalization of $2.01 billion and generates $48.83 million in revenue each year. The biotechnology company earns $-108,900,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

How many employees does BioCryst Pharmaceuticals have?

BioCryst Pharmaceuticals employs 140 workers across the globe.

What is BioCryst Pharmaceuticals' official website?

The official website for BioCryst Pharmaceuticals is

Where are BioCryst Pharmaceuticals' headquarters?

BioCryst Pharmaceuticals is headquartered at 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703.

How can I contact BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The biotechnology company can be reached via phone at (919) 859-1302 or via email at [email protected]

This page was last updated on 4/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.